Literature DB >> 21784622

Metabolic syndrome and atrial fibrillation in patients with essential hypertension.

G Vyssoulis1, E Karpanou, D Adamopoulos, S-M Kyvelou, V Tzamou, A Michaelidis, C Stefanadis.   

Abstract

BACKGROUND AND AIM: Metabolic syndrome (MS) has been recently associated with an increased risk for the development of atrial fibrillation (AF) in the general population. Whether this relation is also apparent in patients with arterial hypertension remains to be clarified. In the present study we sought to investigate the independent association of the MS with the AF in a large cohort of hypertensive patients.
MATERIAL AND METHODS: The study comprised 15,075 consecutive, non-diabetic patients with essential hypertension (age range: 40-95 years, 51.1% males). All subjects underwent a complete clinical and lipidemic profile assessment as well as a standard 12-lead ECG at drug free baseline. MS was diagnosed by using five different definitions, including the National Cholesterol Education Program Third Adult Treatment Panel (ATPIII) and the GISSI Score.
RESULTS: The prevalence of the MS varied from 31.7% to 47.8% according to the each time definition used. In multiple logistic regression analysis, MS was associated with the presence of AF (odds ratio from 1.61 to 1.99, p < 0.001 for all), independenty of the definition used. All ATPIII MS components were found to be independently associated with an increased incidence of AF. The prevalence of AF increased progressively with the severity of the metabolic syndrome as assessed by the number of the metabolic syndrome components (p < 0.001).
CONCLUSION: In non-diabetic patients with essential hypertension, the MS is directly and independently related to the AF prevalence.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21784622     DOI: 10.1016/j.numecd.2011.03.011

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  7 in total

1.  Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic And Racial Differences in Stroke study.

Authors:  Hemal Bhatt; Christopher M Gamboa; Monika M Safford; Elsayad Z Soliman; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2016-05-30

2.  Paradoxical association of lipoprotein measures with incident atrial fibrillation.

Authors:  Samia Mora; Akintunde O Akinkuolie; Roopinder K Sandhu; David Conen; Christine M Albert
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-05-25

Review 3.  Atrial Fibrillation and Metabolic Syndrome: Understanding the Connection.

Authors:  Prabhat Kumar; Anil K Gehi
Journal:  J Atr Fibrillation       Date:  2012-10-06

4.  Low fasting plasma insulin is associated atrial fibrillation in men from a cohort study--the Malmö preventive project.

Authors:  Linda S B Johnson; Tord Juhlin; Gunnar Engström; Peter M Nilsson
Journal:  BMC Cardiovasc Disord       Date:  2014-08-24       Impact factor: 2.298

5.  Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, haemodynamics and health-related quality of life in patients with atrial Fibrillation (SMURF): a protocol for an observational study with a randomised interventional component.

Authors:  Emmanouil Charitakis; Ulla Walfridsson; Fredrik Nyström; Eva Nylander; Anna Strömberg; Urban Alehagen; Håkan Walfridsson
Journal:  BMJ Open       Date:  2015-12-21       Impact factor: 2.692

6.  Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: a nationwide population-based study.

Authors:  Hyo-Jeong Ahn; Kyung-Do Han; Eue-Keun Choi; Jin-Hyung Jung; Soonil Kwon; So-Ryoung Lee; Seil Oh; Gregory Y H Lip
Journal:  Cardiovasc Diabetol       Date:  2021-01-19       Impact factor: 9.951

7.  Obesity phenotypes and their relationships with atrial fibrillation.

Authors:  Szu-Ying Tsai; Hsin-Hao Chen; Hsin-Yin Hsu; Ming-Chieh Tsai; Le-Yin Hsu; Lee-Ching Hwang; Kuo-Liong Chien; Chien-Ju Lin; Tzu-Lin Yeh
Journal:  PeerJ       Date:  2021-10-28       Impact factor: 2.984

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.